-
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary InterventionDJ Angiolillo, U Baber, R Mehran et al. -
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCIK Takahashi, PW Serruys, P Chichareont et al.
-
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journeyD Cao, R Chandiramani, M Chiarito et al.
-
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary InterventionJD McClure, JC Ramsay , C Berry et al.
-
'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trialAS Gamal, H Hara, PW Serruys et al.
-
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical PerspectiveG Tersalvi, L Biasco, GM Cioffi et al.
-
Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery diseaseYiY Zheng, TT Wu, X Xie et al.
-
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial InfarctionS-J Lee, JY Cho, TICO Investigators et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
